Broadvector

Stock Code

BDV

Stock Exchange

ax

Broadvector (BDV) is developing therapies for the treatment of two diseases associated with ageing: early stage prostate cancer and aseptic loosening of prosthetic implants such as artificial hips. In both cases, the new treatment is based upon gene directed enzyme-prodrug therapy ('GDEPT'), a modern strategy that eliminates a target tissue without the need for highly invasive surgery. GDEPT is a sophisticated site-specific drug delivery system that enables drugs of high potency to be made available to target tissues, without having to circulate through the body first.